 | | Vol. 21.28 – 10 August, 2020 |
| |
|
|
| Scientists found that incorporation of the CD3ε cytoplasmic domain into a second-generation chimeric antigen receptor (CAR) improved antitumor activity of CAR-T cells.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Targeting melanosomal proteins or oncogenic CDK4R24C by adoptive cell transfer of the same epitope-specific CD8+ T cells revealed diverse genetic and non-genetic immune escape mechanisms.
[Immunity] |
|
|
|
| Investigators report a rationally designed adeno-associated virus 6 capsid that demonstrated efficiency in lung epithelial cell transduction based on imaging and flow cytometry analysis.
[Nature Communications] |
|
|
|
| Scientists hypothesized that a onetime administration of a serotype 8 adeno-associated virus gene transfer vector coding for the oxidation-resistant variant alpha 1-antitrypsin (AAT) would maintain antiprotease activity under oxidant stress compared with normal AAT.
[JCI Insight] |
|
|
|
| Researchers focused on the paracrine effects of rat dental follicle stem cells (DFSCs) on the inflammation and regeneration of rat injured dental pulp to detect whether DFSCs were a potential candidate for mesenchymal stem cell-based minimally invasive vital pulp therapy.
[Stem Cell Research & Therapy] |
|
|
|
| Scientists applied experimental allogeneic human neural cell therapy after injury in ex vivo spinal cord slices.
[Stem Cell Research & Therapy] |
|
|
|
| The authors showed for the first time that the immune response was altered as a result of syngeneic neonatal cardiomyocyte transplantation after myocardial infarction leading to improved cardiac pump function as observed by magnetic resonance imaging in C57BL/6J mice.
[Cells] |
|
|
|
| Scientists developed an in vivo gene therapy approach to treat canine X-linked severe combined immunodeficiency after hematopoietic stem and progenitor cell mobilization and systemic delivery of the therapeutic vector.
[Human Gene Therapy] |
|
|
|
| Researchers investigated the effect of conditioned medium derived from human embryonic MSCs on experimental ischemic stroke.
[Journal of Cellular Physiology] |
|
|
|
| Scientists treated 14 relapsed or refractory diffuse large B-cell lymphoma patients by combining autologous hematopoietic stem cell transplantation and anti-CD19 chimeric antigen receptor T-cell therapy.
[Immunotherapy] |
|
|
|
| To investigate the effects of human umbilical cord mesenchymal stem cell (HUCMSC) delivery on the acute inflammatory stage of ischemia reperfusion injury, the authors transplanted HUCMSCs or HUCMSCs with cyclosporin A via the coronary artery simultaneously during ischemia reperfusion in pigs.
[Stem Cells and Development] |
|
|
|
| The therapeutic efficacy of LentiVIP was tested in a multiple low-dose STZ-induced animal model of type 1 diabetes. LentiVIP delivery into diabetic animals reduced hyperglycemia, improved glucose tolerance, and prevented weight loss.
[Gene Therapy] |
|
|
|
|
| Meta-analysis showed that stem cell therapy exerts a healing function for burn wounds, mainly through angiogenesis and anti-inflammatory actions.
[Stem Cell Research & Therapy] |
|
|
|
| Researchers show the transplantation protocol for mesenchymal stem cells (MSCs), discuss the potential therapeutic mechanisms, and summarize clinical trials on MSCs for treating ischemic stroke.
[Journal of Neurology] |
|
|
|
| The authors focus on the physiological barriers of cationic liposomes (CLs) against cancer gene therapy and the effects of lipid compositions on governing transfection efficiency, and briefly discuss the impacts of particle size, membrane charge density and surface modification on the fate of CLs in vivo, which may provide guidance for their preclinical studies.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Scientists focus on the therapeutic potential of mesenchymal stem/stromal cells (MSCs). MSCs are available from several tissues, including bone marrow, umbilical cord, and adipose tissue.
[Seminars in Respiratory and Critical Care Medicine] |
|
|
|
|
| Ocugen, Inc. announced the FDA granted the fourth Orphan Drug Designation for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases.
[Ocugen, Inc.] |
|
|
|
| Celularity announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer cells for the treatment of adults with COVID-19.
[Celularity Inc.] |
|
|
|
| Sangamo Therapeutics, Inc. announced that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder and other neurodevelopmental disorders.
[Sangamo Therapeutics] |
|
|
|
|
| May 7 – May 11, 2021
Siena, Italy |
|
|
|
|
|
| | Roswell Park Center for Immunotherapy – Buffalo, New York, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Nanyang Technological University – Singapore, Singapore |
|
|
|
| | Terasaki Institute for Biomedical Innovation – Los Angeles, California, United States |
|
|
|
| | Guangzhou Regenerative Medicine and Health Guangdong Laboratory – Guangzhou, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
